Yang Liu1, Yong Yao, Bing Xing, Wei Lian, Kan Deng, Ming Feng, Renzhi Wang. 1. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China.
Abstract
PURPOSE: Pediatric prolactinomas are rare, especially in children under 14 years of age. In this study, we evaluated the clinical presentation and microsurgical outcome of prolactinomas in prepubertal children. METHODS: Nine patients with prolactinomas who had undergone surgical removal of the tumor before the age of 14 years were included in this retrospective study. Data on their clinical presentation, medications, physical and laboratory evaluations, radiological findings, and long-time follow-up were obtained from their medical records. RESULTS: The main presenting symptom in the four female patients was galactorrhea (n = 4, 100%), whereas the five male patients most commonly presented with headache (n = 4, 80%) and growth retardation (n = 3, 60%). Six (66.6%) of the patients who had undergone transsphenoidal surgery were medication-free postoperatively. In three (33.3%) patients with giant adenomas, complete resection of the tumor was not achieved. One (11.1%) patient received radiotherapy after failed surgical and medical treatment. Postoperatively, electrolyte disturbances occurred in five (55.6%) patients, diabetes insipidus in two (22.2%), and thyroid dysfunction in two (22.2%). These complications resolved spontaneously. During follow-up, growth and puberty were usually normal. CONCLUSIONS: Tumor compressive symptoms and/or gonadal and growth arrest may be the primary clinical presentations of pediatric prolactinoma. Patients who are not candidates for dopamine agonist therapy are best treated surgically, based on the low mortality and high cure rates. Hypopituitarism is a rare complication and may resolve spontaneously. Following successful treatment of a prolactinoma, growth and puberty in these children are normal.
PURPOSE: Pediatric prolactinomas are rare, especially in children under 14 years of age. In this study, we evaluated the clinical presentation and microsurgical outcome of prolactinomas in prepubertal children. METHODS: Nine patients with prolactinomas who had undergone surgical removal of the tumor before the age of 14 years were included in this retrospective study. Data on their clinical presentation, medications, physical and laboratory evaluations, radiological findings, and long-time follow-up were obtained from their medical records. RESULTS: The main presenting symptom in the four female patients was galactorrhea (n = 4, 100%), whereas the five male patients most commonly presented with headache (n = 4, 80%) and growth retardation (n = 3, 60%). Six (66.6%) of the patients who had undergone transsphenoidal surgery were medication-free postoperatively. In three (33.3%) patients with giant adenomas, complete resection of the tumor was not achieved. One (11.1%) patient received radiotherapy after failed surgical and medical treatment. Postoperatively, electrolyte disturbances occurred in five (55.6%) patients, diabetes insipidus in two (22.2%), and thyroid dysfunction in two (22.2%). These complications resolved spontaneously. During follow-up, growth and puberty were usually normal. CONCLUSIONS:Tumor compressive symptoms and/or gonadal and growth arrest may be the primary clinical presentations of pediatric prolactinoma. Patients who are not candidates for dopamine agonist therapy are best treated surgically, based on the low mortality and high cure rates. Hypopituitarism is a rare complication and may resolve spontaneously. Following successful treatment of a prolactinoma, growth and puberty in these children are normal.
Authors: Caroline A Steele; Ian A MacFarlane; Joanne Blair; Daniel J Cuthbertson; Mohammed Didi; Conor Mallucci; Mohsen Javadpour; Christina Daousi Journal: Eur J Endocrinol Date: 2010-08-04 Impact factor: 6.664
Authors: Shrikrishna V Acharya; Raju A Gopal; Tushar R Bandgar; Shashank R Joshi; Padma S Menon; Nalini S Shah Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: Erdal Eren; Şenay Yapıcı; Esra Deniz Papatya Çakır; Latife Aytekin Ceylan; Halil Sağlam; Ömer Tarım Journal: J Clin Res Pediatr Endocrinol Date: 2011-06-08
Authors: Maria de Fátima de Magalhães Gonzaga; Lucas Faria de Castro; Luciana Ansaneli Naves; José Luiz Mendonça; Benicio Oton de Lima; Iruena Kessler; Luiz Augusto Casulari Journal: Front Endocrinol (Lausanne) Date: 2018-11-13 Impact factor: 5.555